Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema cream aims to end sleepless nights

NCT ID NCT05696392

Symptom relief Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a prescription cream called ruxolitinib on adults with mild-to-moderate eczema who had trouble sleeping because of their condition. The goal was to see if the cream could help them sleep longer and better. The study was stopped early, but it involved 47 participants who used the cream and wore a sleep-tracking ring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

47 people

The number who actually took part.

Started

Mar 2023

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has clinically confirmed diagnosis of active AD according to Hanifin and Rajka (1980) criteria. * Has at least a 2-year history of AD (information obtained from medical chart, participant's physician, or directly from the participant). * Has an overall BSA affected by AD of 3%-20% (excluding scalp) at the screening and baseline visits. * Has an IGA score ≥ 2 at the screening and baseline visits. * Has an Itch NRS score ≥ 4 at the screening and baseline visits. * Willing to complete the once-daily Itch NRS (24-hour recall period) entries at approximately the same time each day during the study. * Agrees to maintain a regular sleep schedule during the study period. * Willing and able to follow required study procedures for measuring sleep for the duration of the study. Exclusion Criteria: * Currently using a wearable or other device for monitoring sleep patterns and unwilling to discontinue its use during the study. * Currently has a schedule that includes nighttime work shifts. * Has had significant flares or unstable course in AD (ie, condition worsened significantly or required significant change in medications, as per medical judgment) in the previous 4 weeks before screening (information obtained from medical chart, participant's physician, or directly from the participant). * Has received any ultraviolet B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to the screening period. * Has had psoralen plus ultraviolet A treatment within 4 weeks prior to the screening period. * Has received a nonbiological investigational product or device within 4 weeks prior to the screening period, or is currently enrolled in another investigational drug study. * Has received treatment with JAK inhibitors (systemic or topical) within 4 weeks prior to the screening period. * Has had prior treatment with a JAK inhibitor that was discontinued for safety reasons or tolerance problems. * Has a known or suspected allergy to ruxolitinib or any component of the study drug.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Ark Clinical Research

    Long Beach, California, 90815, United States

  • Arlington Research Center

    Arlington, Texas, 76011, United States

  • Beth Israel Deaconess Medical Center (Bidmc)

    Boston, Massachusetts, 02215, United States

  • Ciocca Dermatology Pa

    Miami, Florida, 33173, United States

  • Clinical Research Center of the Carolinas

    Charleston, South Carolina, 29407, United States

  • Clinical Research Partners Llc

    Richmond, Virginia, 23226, United States

  • Dawes Fretzin Clinical Research Group Llc

    Indianapolis, Indiana, 46250, United States

  • Dermatology Specialists Research Indiana

    Clarksville, Indiana, 47129, United States

  • Dermatology Specialists of Spokane

    Spokane, Washington, 99202, United States

  • Driven Research Llc

    Coral Gables, Florida, 33134, United States

  • Empire Dermatology

    East Syracuse, New York, 13057, United States

  • Essential Dermatology

    Natick, Massachusetts, 01760, United States

  • First Oc Dermatology

    Fountain Valley, California, 92708, United States

  • Gw Training Center

    Washington D.C., District of Columbia, 20037, United States

  • Jordan Valley Dermatology Center

    South Jordan, Utah, 84095, United States

  • Knight Cancer Institute At Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Northeast Dermatology Associates

    Methuen, Massachusetts, 01844, United States

  • Ohio Pediatric Research Association

    Dayton, Ohio, 45414, United States

  • Oregon Dermatology and Research Center

    Portland, Oregon, 97210, United States

  • Pi Coor Clinical Research Llc

    Burke, Virginia, 22015, United States

  • Sadick Dermatology

    New York, New York, 10075, United States

  • Skin Care Research, Llc

    Boca Raton, Florida, 33486, United States

  • Skin Care Research, Llc Scr Hollywood

    Hollywood, Florida, 33021, United States

  • Skin Sciences Pllc

    Louisville, Kentucky, 40217, United States

  • Skin Search of Rochester

    Rochester, New York, 14623, United States

  • Suny Downstate Health Sciences University

    Brooklyn, New York, 11203, United States

  • Trueblue Clinical Research

    Tampa, Florida, 33609, United States

  • University of Florida Health Dermatology-Springhill

    Gainesville, Florida, 32606, United States

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

  • Washington University School of Medicine Dermatology

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.